Get the Daily Brief
Latest Biotech News
En Carta wins FDA breakthrough device tag for microneedle Lyme test
Paris‑based En Carta Diagnostics received Breakthrough Device designation from the FDA for EC Pocket Lyme, a point‑of‑care molecular test that detects Borrelia directly from skin interstitial...
Sensorion raises €60M as Sanofi takes strategic stake to back hearing programs
Sensorion SA closed a €60 million financing round, including a €20 million strategic investment from Sanofi, to advance a clinical program for SENS‑601 and other hearing‑loss candidates. The...
Cellares secures $257M to scale global cell‑therapy manufacturing and eye IPO
Cellares raised $257 million in a Series D round to expand commercial cell‑therapy manufacturing capabilities and position the company for a planned 2027 IPO. The funding will support deployment...
Eclipsebio acquires Terrain Bio to fuse ML RNA design with sequencing analytics
RNA genomics firm Eclipsebio acquired Terrain Bio to accelerate an end‑to‑end RNA design, manufacturing, and validation platform. Terrain’s machine‑learning RNA analytics will be integrated with...
Danaher posts stronger‑than‑expected Q4 as bioprocessing sales drive growth
Danaher reported Q4 revenue of $6.84 billion, up about 5% year‑over‑year and topping analyst estimates, powered by continued strength in bioprocessing and life‑sciences consumables. The...
Biopharma Sentiment Index climbs — optimism returns but uncertainty remains
The Biopharma Sentiment Index rose to 90 in Q1 2026, up from 78 the prior quarter, signaling a broad improvement in industry mood driven by dealmaking and capital access. The index, produced by...
FDA lifts hold on one Intellia trial: Magnitude-2 cleared, cardiomyopathy study remains paused
The U.S. Food and Drug Administration has lifted a clinical hold on Intellia Therapeutics’ Magnitude-2 Phase 3 trial testing CRISPR therapy nexiguran ziclumeran (nex‑z) for transthyretin...
FDA halts Regenxbio gene therapy trials after child develops brain tumor
The FDA paused two Regenxbio gene therapy trials after the company reported a child participant developed a brain tumor, the company and STAT reported. The affected programs aim to replace broken...
Lilly inks up-to-$1.12B Seamless pact: recombinase editing for hearing loss
Eli Lilly struck a global research and licensing agreement with TU Dresden spinout Seamless Therapeutics to deploy programmable recombinases for genetic hearing‑loss therapies, with deal economics...
Cellares raises $257M: cell therapy contract manufacturer scales toward IPO
Cellares closed a $257 million Series D round to accelerate global expansion of its automated cell therapy manufacturing platform and to prepare for a planned 2027 IPO. The funding is intended to...
Roche’s mid‑stage obesity shot posts double‑digit loss... Phase 3 next
Roche reported Phase 2 results for its dual GLP‑1/GIP agonist CT‑388 showing roughly 22.5% placebo‑adjusted weight loss at 48 weeks, and announced plans to advance the candidate into Phase 3 by...
Parse and Graph join to build massive immune perturbation atlas
Parse Biosciences and Graph Therapeutics formed a strategic partnership to generate a large, functional immune perturbation atlas by combining Graph’s patient‑derived perturbation assays with...
Eclipsebio buys Terrain Bio: RNA design meets sequencing analytics
Eclipsebio acquired Terrain Bio to accelerate an end‑to‑end RNA therapeutic platform that couples machine‑learning RNA design with deep sequencing analytics. Eclipsebio said the acquisition will...
iXCells and Rosebud pair up on organoids... rare disease models scaled
iXCells Biotechnologies and Rosebud Biosciences announced a partnership to combine iXCells’ scalable iPSC platform (iPSCore) with Rosebud’s AI‑driven organoid generation to produce complex 3D...
AI‑designed anti‑CRISPRs: de novo proteins switch off Cas13 fast
An academic team used AI‑accelerated protein design to generate new anti‑CRISPR proteins (AIcrs) that inhibit Cas13a, producing functional inhibitors in bacterial and human cells within eight...
In vivo CAR‑T reduces liver fibrosis: stellate cell targeting shows reversal
Mount Sinai researchers reported an in vivo CAR‑T approach that selectively targets fibroblast activation protein alpha (FAP)‑expressing stellate cells and reduced liver fibrosis in models of...
FDA lifts hold on Intellia CRISPR trial – one Phase 3 resumes after liver event
The U.S. Food and Drug Administration has lifted a clinical hold on Intellia Therapeutics’ Magnitude-2 Phase 3 trial of its CRISPR/Cas9 therapy nexiguran ziclumeran (nex‑z) for transthyretin...
FDA clears Life Biosciences reprogramming study – first human test of age‑rewind approach
The U.S. FDA has approved Life Biosciences’ first-in-human trial of a cell reprogramming gene therapy intended to reverse aspects of cellular aging. The initial study will test ER‑100 in patients...
Roche’s GLP‑1/GIP CT‑388 posts weight‑loss signal — company pushes to Phase 3
Roche announced Phase 2 results for CT‑388 showing a placebo‑adjusted weight loss of about 22.5% at 48 weeks (22.5% excluding discontinuations; ~18.3% when counting dropouts), and said it will...
Eclipsebio buys Terrain Bio – AI design meets sequencing analytics for RNA drugs
Eclipsebio has acquired Terrain Bio to accelerate an integrated platform for RNA therapeutic design, manufacturing and validation. The deal combines Terrain’s machine‑learning RNA analytics with...